Intelligence · Patents
Patents expiring in 2038
Annual patent cliff calendar for 2038 — US pharmaceutical patents by expiration date.
- Patents
- 1,509
Quick answer
1,509 indexed pharmaceutical patents have expiration dates in 2038. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 9933434
Therapeutic antibodies against ROR-1 protein and methods for use of same
granted -
US 9932406
Human monoclonal antibodies specific for glypican-3 and use thereof
granted -
US 9931418
Compositions for the delivery of RNA and drugs into cells
granted -
US 9932564
Recombinant isfahan viral vectors
granted -
US 9932372
Designer peptide-based PCV2 vaccine
granted -
US 9932593
Compositions and methods for inhibiting expression of CD274/PD-L1 gene
granted -
US 9931412
Targeted theranostics
granted -
US 9932322
Method for producing sulfonyl chloride compound
granted -
US 9931415
Pyrrolobenzodiazepine-antibody conjugates
granted -
US 9938344
Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
granted -
US 9938258
Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof
granted -
US 9937243
Sialylated glycoprotein compositions and uses thereof
granted -
US 9937129
Materials and methods for delivering compositions to selected tissues
granted -
US 9938236
Antiviral agents against HBV infection
granted -
US 9937222
Modulators of complement activity
granted -
US 9937256
Hydrogels for delivery of therapeutic compounds
granted -
US 9937217
Method of inhibiting ABCG2 and related treatments
granted -
US 9937228
Treatment of myocardial infarction by inhibiting the action of mAKAPβ
granted -
US 9937266
Oligomer-containing benzamide-based compounds
granted -
US 9938259
Therapeutic compositions and related methods of use
granted -
US 9937156
Modulation of MRTF-A activity in pathologic fibrosis and wound healing
granted -
US 9937159
Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
granted -
US 9937141
Carcinoma diagnosis and treatment, based on ODC1 genotype
granted -
US 9937196
Genomic sequence of avian paramyxovirus type 2 and uses thereof
granted -
US 9938270
Mono-phosphate salt of 6-fluoro-2-[4-(pyridin-2-yl)but-3-yn-1-yl]imidazo[1,2A]pyridine (dipraglurant) and polymorphs thereof as negative allosteric modulator of MGLU5 receptor
granted -
US 9937191
Inhibition of HIV infection through chemoprophylaxis
granted -
US 9937155
Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
granted -
US 9937207
Targeted disruption of T cell receptor genes using talens
granted -
US 9937157
Modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors
granted -
US 9938272
Hydrazine compound as blood coagulation factor Xa inhibitor
granted -
US 9938257
Substituted heteroaryl compounds and methods of use
granted -
US 9938582
Recurrent gene fusions in prostate cancer
granted -
US 9938526
Manganese ion coated nanoparticles for delivery of compositions into the central nervous system by nasal insufflation
granted -
US 9938589
Compositions and methods for detecting human pegivirus 2 (HPgV-2)
granted -
US 9938350
Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof
granted -
US 9938500
Hemangio-colony forming cells
granted -
US 9938516
Non-natural amino acid tRNA synthetases for para-methylazido-L-phenylalanine
granted -
US 9937192
Combination therapy to treat mycobacterium diseases
granted -
US 9938339
Method for treating an eye disease or disorder by administering an antibody that binds angiopoietin-2
granted -
US 9938345
Human antibodies to PD-L1
granted -
US 9938531
Compositions and methods for inhibiting expression of RRM2 genes
granted -
US 9938353
Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
granted -
US 9944603
Compounds and methods for the treatment of cystic fibrosis
granted -
US 9943539
2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations
granted -
US 9944926
Induced exon inclusion in spinal muscle atrophy
granted -
US 9943604
Targeted therapeutic nucleosides and their use
granted -
US 9944740
Sugar containing, amphiphilic copolymers
granted -
US 9944652
Deuterated amlexanox
granted
Frequently asked questions
How many pharma patents expire in 2038?
1,509 published patents in our USPTO index have expiration dates falling in calendar year 2038.